Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by brad129on Mar 22, 2022 11:08am
126 Views
Post# 34534411

RE:RE:RE:Question

RE:RE:RE:Question

Hey thanks for that, didn't put those pieces together,my bad. This is the discussion I would love to see more of. We are either in or out of this on our own personal beliefs, but we can have good discussion without the biased attacks. Even those who are out (looking for a re entry) can be civil and have an opinion.



molotov420 wrote: haha, better start chewing now. Dont think they are ever going to spell out "Aristotle Revenue" for you. Lab Revenue is likely as clear as it will get. 

The 400K is shown on the last financial statement page 28/29. Clinical consultation is HC. They show 273K+115K deferred. Pretty close to 400K in the month of Sept. 

 

<< Previous
Bullboard Posts
Next >>